Acs Research - Theorylab

Darren Roblyer and his lab has developed a small, painless wearable probe that a patient can wear over her tumor. It’s flexible and conforms to the shape of the patient’s breast, and it uses light to monitor the tumor’s response to chemotherapy. Why is this important? It offers a new way to assess treatment response in real time to see if a patient is responding to pre-surgical chemotherapy, providing a pathway to personalize the treatment plan for each patient. Dr. Roblyer is a two-time American Cancer Society grantee and Associate Professor in the Department of Biomedical Engineering at Boston University 2:27 – On why neoadjuvant (or pre-surgical) chemotherapy is important 3:45 – The challenges of pre-surgical chemotherapy 5:34 – An opportunity to adapt treatments for specific patients 7:54 – How his lab uses a wearable probe to monitor breast tumors 10:48 – How the technology can help identify who’s responding to chemotherapy and who’s not in the first week of therapy 12:21 – On why it’s safe and